Overview

Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder

Status:
Withdrawn
Trial end date:
2005-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to test a candidate drug, Org 24448,in a phase II clinical trial in adult patients with moderately treatment-resistant unipolar major depressive disorder.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Dennis Charney
Collaborator:
National Institutes of Health (NIH)
Criteria
Inclusion Criteria:

- Clinical Diagnosis of MDD

- Have not responded to an adequate trial of one antidepressant in the current episode
or have not completed antidepressant trials due to intolerance to ≤3 antidepressant
medications in the current or a previous episode

Exclusion Criteria:

- Presence of psychotic features, OCD, drug or alcohol dependency with the preceding 3
months